Abstract: Disclosed is a topical therapeutic agent for ophthalmic diseases, which comprises a compound capable of binding specifically to a DNA sequence. More preferably disclosed is a topical therapeutic agent for ophthalmic diseases, which comprise a pyrrole-imidazole polyamide having a specific structure. The topical therapeutic agent for ophthalmic diseases comprises a pyrrole-imidazole polyamide which can inhibit transforming growth factor-? gene and matrix metalloproteinase 9 gene.

Abstract: A TGF-? gene expression inhibitor containing a pyrrole-immidazole polyamide comprising an N-methylpyrrole unit (hereinafter also referred to as Py), an N-methylimidazole unit (hereinafter also referred to as Im) and a ?-aminobutyric acid unit which can be folded into an U-shaped conformation at the above-described ?-aminobutyric acid unit site in a minor groove of a double-stranded region (hereinafter referred to as the target region) containing a part or the whole of the following base sequence (SEQ ID NO: 2) corresponding to ?450 to ?310 of human transforming growth factor ?1 (hereinafter also referred to as h TGF-?1) promoter and a strand complementary thereto and in which a Py/Im pair, an Im/Py pair and a PY/Py pair correspond respectively to a C-G base pair, a G-C base pair and an A-T base pair and a T-A base pair.

Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained.

Abstract: A TGF-? gene expression inhibitor containing a pyrrole-imidazole polyamide having N-methylimidazole unit (hereinafter also referred to as Py), N-methylimidazole unit (hereinafter also referred to as Im) and ?-aminobutyrate unit which can be holded into an U-shaped conformation at the ?-aminobutyrate unit in the minor groove in a double helix region (hereinafter referred to as the target region) containing a complementary chain corresponding to the sequence at the ?557 to ?536 in the base sequence of a human transforming growth factor ?1 (hereinafter also referred to as hTGF-?1) promoter, either as a whole or a part thereof: TAAAGGAGAGCAATTCT-TACAG (SEQ ID NO: 1) wherein a Py/Im pair corresponds to a C-G base pair, an Im/Py pair corresponds to a G-C base pair, and Py/Py pairs correspond respectively to an A-A base pair and a T-A base pair.

Abstract: A synthesis method for pyrrole-imidazole polyamide is automated at a higher level and can produce a product with a high yield in a more stable manner. In a solid phase synthesis method, the automated synthesis of a polyimide can be promoted by using HCTU as a condensation-activator, the yield of a product can be increased by charging a monomer in a solid form, and a pyrrole-imidazole polyamide having any sequence can be synthesis by combining the synthesis method with a manual synthesis with an acid chloride.

Abstract: A TGF-? gene expression inhibitor containing a pyrrole-immidazole polyamide comprising an N-methylpyrrole unit (hereinafter also referred to as Py), an N-methylimidazole unit (hereinafter also referred to as Im) and a ?-aminobutyric acid unit which can be folded into an U-shaped conformation at the above-described ?-aminobutyric acid unit site in a minor groove of a double-stranded region (hereinafter referred to as the target region) containing a part or the whole of the following base sequence (SEQ ID NO: 2) corresponding to ?450 to ?310 of human transforming growth factor ?1 (hereinafter also referred to as h TGF-?1) promoter and a strand complementary thereto and in which a Py/Im pair, an Im/Py pair and a PY/Py pair correspond respectively to a C-G base pair, a G-C base pair and an A-T base pair and a T-A base pair.

Abstract: A TGF-? gene expression inhibitor containing a pyrrole-imidazole polyamide having N-methylimidazole unit (hereinafter also referred to as Py), N-methylimidazole unit (hereinafter also referred to as Im) and ?-aminobutyrate unit which can be holded into an U-shaped conformation at the ?-aminobutyrate unit in the minor groove in a double helix region (hereinafter referred to as the target region) containing a complementary chain corresponding to the sequence at the -557 to -536 in the base sequence of a human transforming growth factor ?1 (hereinafter also referred to as hTGF-?1) promoter, either as a whole or a part thereof: TAAAGGAGAGCAATTCT-TACAG (SEQ ID NO: 1) wherein a Py/Im pair corresponds to a C-G base pair, an Im/Py pair corresponds to a G-C base pair, and Py/Py pairs correspond respectively to an A-A base pair and a T-A base pair.

Abstract: To provide infusion therapy that can effectively transluminally deliver drugs or the like to a target spot without invading areas other than a diseased area. The infusion therapy is for administering a drug, cells or the like, or inserting a treatment instrument into the target diseased area. A blood vessel area including a bifurcated blood vessel connecting to the diseased area is occluded at the distal and the proximal region thereof to form an occluded area, and the drugs or the like are pumped and supplied to the occluded area, which causes the drugs or the like to flow retrogressively and retentively in the bifurcated blood vessel connecting in the occluded area, and be infused and administered to the diseased area.

Abstract: A balloon catheter capable of adjusting a position to inflate a balloon in the axial direction of a catheter is provided.

Abstract: A ribozyme comprising the following nucleotide sequence (SEQ ID NO:14) (I): 3?-GUGCCCCA GUACGGUG-5? ??????????A C ??????????A??UGA ??????????G??AGU ??????????N3 N1 ???????????N2 wherein A, C, G and U represent a ribonucleotide whose base component is adenine, cytosine, guanine and uracil, respectively, N1 and N3 are at least one pair of nucleotides capable of forming a complementary base pair with each other, and N2 is at least three nucleotides capable of forming a loop.

Abstract: To provide a catheter and a method for infusion therapy that can effectively transluminally deliver drugs or the like to a target spot without invading areas other than a diseased area. The catheter is a balloon catheter for insertion into a blood vessel in which four lumens extending along an axis are formed in one catheter body, and two balloons are arranged axially in parallel. The plurality of lumens include: an infusion lumen that communicates with an infusion hole between the two balloons; balloon lumens that communicate with insides of the two balloons to expand the balloons; and a guide lumen that also serves as a bypass lumen that communicates with an outside of the catheter body in each position distal and proximal, which is outside of the two balloons with respect to a tip a of the catheter body, and bypasses an occluded area formed by the two balloons to allow blood flow.

Abstract: To provide infusion therapy that can effectively transluminally deliver drugs or the like to a target spot without invading areas other than a diseased area. The infusion therapy is for administering a drug, cells or the like, or inserting a treatment instrument into the target diseased area. A blood vessel area including a bifurcated blood vessel connecting to the diseased area is occluded at the distal and the proximal region thereof to form an occluded area, and the drugs or the like are pumped and supplied to the occluded area, which causes the drugs or the like to flow retrogressively and retentively in the bifurcated blood vessel connecting in the occluded area, and be infused and administered to the diseased area.